AstraZeneca 3Q Revenues: $7.2 billion (+10%, +6% at Constant Exchange Rates) 3Q Earnings: $1.4 billion (-15%) YTD Revenues: $21.4 billion (+11%, +7% CER) YTD Earnings: $4.4 billion (-6%) Comments: In a deliberately obfuscatory earnings note, AZ posted revenue growth of approximately $600 million in 3Q7, reaching $7.1 billion. Global sales of Crestor grew 39% (CER) to $691 million, but the company reported that a generic challenge to AZ’s patent was issued on Oct. 30. Nexium ...